Search reports, ask a question, or jump to a page.
The problem
Intervention: Tiotropium Respimat add-on therapy to inhaled corticosteroids, with or without other maintenance therapies
Who it was tested with: Children and adolescents over 6 years old with symptomatic moderate or severe asthma.
Experience from people who deliver programmes: stories, case studies and lessons learned. Valuable for understanding how and why, and for spotting what to test next, but not a measure of effect.
"A large clinical trial program has been conducted in children, adolescents, and adults across the spectrum of asthma severity. Findings from these clinical studies and pooled analyses in children and adolescents with symptomatic moderate or severe asthma have demonstrated that tiotropium Respimat ® as add-on to inhaled corticosteroids, with or without other maintenance therapies, is a well-tolerated and efficacious bronchodilator, showing improved lung function and trends towards improved asthma control." The document synthesizes evidence from multiple controlled trials demonstrating benefit, meeting criteria for experimental evidence tier.
This review does not provide specific effect sizes, sample sizes, or statistical significance levels for the outcomes reported. The document notes trends towards improved asthma control rather than definitive improvements.
Across countries and designs
1 study · 1 country
